More on GILD
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $145.14 |
|
|||
| Open | $143.56 | ||||
| 52 Wk High | $108.63 | ||||
| 52 Wk Low | $71.39 | ||||
| Day High | $144.65 | ||||
| Day Low | $142.77 | ||||
| P/E | 79.52 | ||||
| EPS | $1.81 | ||||
| Volume | 4,921,303 | ||||
- BofA Securities Reiterates Buy Rating on Gilead Sciences (GILD) as weekly Yeztugo scripts accelerate
- Form 4 GILEAD SCIENCES, INC. For: Feb 27 Filed by: Dickinson Andrew D
- Form 4 GILEAD SCIENCES, INC. For: Feb 27 Filed by: Mercier Johanna
- Form 4 GILEAD SCIENCES, INC. For: Feb 27 Filed by: Berger Dietmar
- Form 4 GILEAD SCIENCES, INC. For: Feb 27 Filed by: Cain Wettan Keeley M
- Form 4 GILEAD SCIENCES, INC. For: Feb 27 Filed by: O'Day Daniel Patrick
- Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia
- Form 144 GILEAD SCIENCES, INC. Filed by: O'Day Daniel Patrick
- Gilead HIV drug combination maintains viral suppression in phase 3 trials
- Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy
Entities mentioned with GILD
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Options | View Related Stories »
- Show More...
